Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 2003 Apr 15;371(Pt 2):277–287. doi: 10.1042/BJ20021508

The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.

Niels Behrendt 1, Karin List 1, Peter A Andreasen 1, Keld Danø 1
PMCID: PMC1223308  PMID: 12534347

Abstract

The reciprocal pro-enzyme activation system of plasmin, urokinase-type plasminogen activator (uPA) and their respective zymogens is a potent mechanism in the generation of extracellular proteolytic activity. Plasminogen activator inhibitor type 1 (PAI-1) acts as a negative regulator. This system is complicated by a poorly understood intrinsic reactivity of the uPA pro-enzyme (pro-uPA) before proteolytic activation, directed against both plasminogen and PAI-1. We have studied the integrated activation mechanism under the repression of PAI-1 in a purified system. A covalent reaction between pro-uPA and PAI-1 was positively demonstrated but the reaction of PAI-1 with two-chain uPA was found to be at least 1000-fold faster. However, in spite of this very fast inhibition, two-chain uPA still became the dominant plasminogen activator when plasminogen was incubated with pro-uPA and PAI-1. The activity pattern observed under these conditions revealed an initial lag phase, followed by a continuous generation of minute amounts of active two-chain uPA, this uPA having a short lifetime before inhibition but still succeeding to generate new plasmin activity, thus preventing a complete inactivation of the feedback system. This property of the activation system was retained even in the simultaneous presence of PAI-1 and alpha(2)-antiplasmin. Addition of soluble uPA receptor to the system did not change the role of pro-uPA and the same pattern was observed when pro-uPA was bound to the uPA receptor on U937 cells. The present mechanism maintains the system at standby level and may be triggered to increased activity without the need for an external initiating event.

Full Text

The Full Text of this article is available as a PDF (290.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen P. A., Egelund R., Petersen H. H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000 Jan 20;57(1):25–40. doi: 10.1007/s000180050497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Andreasen P. A., Kjøller L., Christensen L., Duffy M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997 Jul 3;72(1):1–22. doi: 10.1002/(sici)1097-0215(19970703)72:1<1::aid-ijc1>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  3. Andreasen P. A., Nielsen L. S., Kristensen P., Grøndahl-Hansen J., Skriver L., Danø K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem. 1986 Jun 15;261(17):7644–7651. [PubMed] [Google Scholar]
  4. Behrendt N., Danø K. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system. FEBS Lett. 1996 Sep 9;393(1):31–36. doi: 10.1016/0014-5793(96)00849-6. [DOI] [PubMed] [Google Scholar]
  5. Behrendt N., Danø K. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system. FEBS Lett. 1996 Sep 9;393(1):31–36. doi: 10.1016/0014-5793(96)00849-6. [DOI] [PubMed] [Google Scholar]
  6. Behrendt N., Danø K. Reply to comment on 'Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system' (A. A-R. Higazi) FEBS Lett. 1997 Feb 3;402(2-3):293–294. doi: 10.1016/s0014-5793(96)01534-7. [DOI] [PubMed] [Google Scholar]
  7. Behrendt N., Jensen O. N., Engelholm L. H., Mørtz E., Mann M., Danø K. A urokinase receptor-associated protein with specific collagen binding properties. J Biol Chem. 2000 Jan 21;275(3):1993–2002. doi: 10.1074/jbc.275.3.1993. [DOI] [PubMed] [Google Scholar]
  8. Behrendt N., Ronne E., Dano K. Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J Biol Chem. 1996 Sep 13;271(37):22885–22894. doi: 10.1074/jbc.271.37.22885. [DOI] [PubMed] [Google Scholar]
  9. Bode W., Schwager P., Huber R. The transition of bovine trypsinogen to a trypsin-like state upon strong ligand binding. The refined crystal structures of the bovine trypsinogen-pancreatic trypsin inhibitor complex and of its ternary complex with Ile-Val at 1.9 A resolution. J Mol Biol. 1978 Jan 5;118(1):99–112. doi: 10.1016/0022-2836(78)90246-2. [DOI] [PubMed] [Google Scholar]
  10. Brodrick J. W., Glaser C. B., Largman C., Geokas M. C., Graceffo M., Fassett M., Maeda H. Interaction of chymotrypsinogens with alpha 1-protease inhibitor. Biochemistry. 1980 Oct 14;19(21):4865–4870. doi: 10.1021/bi00562a025. [DOI] [PubMed] [Google Scholar]
  11. Bugge T. H., Flick M. J., Danton M. J., Daugherty C. C., Romer J., Dano K., Carmeliet P., Collen D., Degen J. L. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5899–5904. doi: 10.1073/pnas.93.12.5899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
  13. Danø K., Rømer J., Nielsen B. S., Bjørn S., Pyke C., Rygaard J., Lund L. R. Cancer invasion and tissue remodeling--cooperation of protease systems and cell types. APMIS. 1999 Jan;107(1):120–127. doi: 10.1111/j.1699-0463.1999.tb01534.x. [DOI] [PubMed] [Google Scholar]
  14. Egelund R., Rodenburg K. W., Andreasen P. A., Rasmussen M. S., Guldberg R. E., Petersen T. E. An ester bond linking a fragment of a serine proteinase to its serpin inhibitor. Biochemistry. 1998 May 5;37(18):6375–6379. doi: 10.1021/bi973043+. [DOI] [PubMed] [Google Scholar]
  15. Ellis V., Behrendt N., Danø K. Cellular receptor for urokinase-type plasminogen activator: function in cell-surface proteolysis. Methods Enzymol. 1993;223:223–233. doi: 10.1016/0076-6879(93)23048-r. [DOI] [PubMed] [Google Scholar]
  16. Ellis V., Behrendt N., Danø K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem. 1991 Jul 5;266(19):12752–12758. [PubMed] [Google Scholar]
  17. Ellis V., Danø K. Plasminogen activation by receptor-bound urokinase. Semin Thromb Hemost. 1991 Jul;17(3):194–200. doi: 10.1055/s-2007-1002609. [DOI] [PubMed] [Google Scholar]
  18. Ellis V., Danø K. Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation. J Biol Chem. 1993 Mar 5;268(7):4806–4813. [PubMed] [Google Scholar]
  19. Ellis V. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase. J Biol Chem. 1996 Jun 21;271(25):14779–14784. doi: 10.1074/jbc.271.25.14779. [DOI] [PubMed] [Google Scholar]
  20. Ellis V., Scully M. F., Kakkar V. V. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem. 1989 Feb 5;264(4):2185–2188. [PubMed] [Google Scholar]
  21. Ellis V., Wun T. C., Behrendt N., Rønne E., Danø K. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem. 1990 Jun 15;265(17):9904–9908. [PubMed] [Google Scholar]
  22. Frenette G., Tremblay R. R., Lazure C., Dube J. Y. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int J Cancer. 1997 May 29;71(5):897–899. doi: 10.1002/(sici)1097-0215(19970529)71:5<897::aid-ijc31>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  23. Higazi A. A. Commentary on: 'Effect of purified soluble urokinase receptor on the plasminogen prourokinase activation system' by N. Behrendt and K. Dano, FEBS Letters, 393 (1996) 31-36. FEBS Lett. 1997 Feb 3;402(2-3):291–292. doi: 10.1016/s0014-5793(96)01533-5. [DOI] [PubMed] [Google Scholar]
  24. Higazi A. A., Mazar A., Wang J., Reilly R., Henkin J., Kniss D., Cines D. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood. 1996 May 1;87(9):3545–3549. [PubMed] [Google Scholar]
  25. Higazi A., Cohen R. L., Henkin J., Kniss D., Schwartz B. S., Cines D. B. Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor. J Biol Chem. 1995 Jul 21;270(29):17375–17380. doi: 10.1074/jbc.270.29.17375. [DOI] [PubMed] [Google Scholar]
  26. Huntington J. A., Read R. J., Carrell R. W. Structure of a serpin-protease complex shows inhibition by deformation. Nature. 2000 Oct 19;407(6806):923–926. doi: 10.1038/35038119. [DOI] [PubMed] [Google Scholar]
  27. Håkansson H. O., Borgström A., Ohlsson K. Porcine pancreatic cationic pro-elastase. Studies on the activation, turnover and interaction with plasma proteinase inhibitors. Biol Chem Hoppe Seyler. 1991 Jul;372(7):465–472. doi: 10.1515/bchm3.1991.372.2.465. [DOI] [PubMed] [Google Scholar]
  28. Ichinose A., Fujikawa K., Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem. 1986 Mar 15;261(8):3486–3489. [PubMed] [Google Scholar]
  29. Kobayashi H., Schmitt M., Goretzki L., Chucholowski N., Calvete J., Kramer M., Günzler W. A., Jänicke F., Graeff H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem. 1991 Mar 15;266(8):5147–5152. [PubMed] [Google Scholar]
  30. Largman C., Brodrick J. W., Geokas M. C., Sischo W. M., Johnson J. H. Formation of a stable complex between human proelastase 2 and human alpha 1-protease inhibitor. J Biol Chem. 1979 Sep 10;254(17):8516–8523. [PubMed] [Google Scholar]
  31. Lawrence D. A., Ginsburg D., Day D. E., Berkenpas M. B., Verhamme I. M., Kvassman J. O., Shore J. D. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J Biol Chem. 1995 Oct 27;270(43):25309–25312. doi: 10.1074/jbc.270.43.25309. [DOI] [PubMed] [Google Scholar]
  32. Lijnen H. R., De Cock F., Collen D. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor. Eur J Biochem. 1994 Sep 1;224(2):567–574. doi: 10.1111/j.1432-1033.1994.00567.x. [DOI] [PubMed] [Google Scholar]
  33. Lijnen H. R. Elements of the fibrinolytic system. Ann N Y Acad Sci. 2001;936:226–236. doi: 10.1111/j.1749-6632.2001.tb03511.x. [DOI] [PubMed] [Google Scholar]
  34. List K., Jensen O. N., Bugge T. H., Lund L. R., Ploug M., Danø K., Behrendt N. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice. Biochemistry. 2000 Jan 25;39(3):508–515. doi: 10.1021/bi991701f. [DOI] [PubMed] [Google Scholar]
  35. Manchanda N., Schwartz B. S. Interaction of single-chain urokinase and plasminogen activator inhibitor type 1. J Biol Chem. 1995 Aug 25;270(34):20032–20035. doi: 10.1074/jbc.270.34.20032. [DOI] [PubMed] [Google Scholar]
  36. Matheson N. R., van Halbeek H., Travis J. Evidence for a tetrahedral intermediate complex during serpin-proteinase interactions. J Biol Chem. 1991 Jul 25;266(21):13489–13491. [PubMed] [Google Scholar]
  37. Nielsen L. S., Andreasen P. A., Grøndahl-Hansen J., Huang J. Y., Kristensen P., Danø K. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification. Thromb Haemost. 1986 Apr 30;55(2):206–212. [PubMed] [Google Scholar]
  38. Nielsen L. S., Grøndahl-Hansen J., Andreasen P. A., Skriver L., Zeuthen J., Danø K. Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies. J Immunoassay. 1986;7(3):209–228. doi: 10.1080/01971528608060467. [DOI] [PubMed] [Google Scholar]
  39. Nielsen L. S., Hansen J. G., Skriver L., Wilson E. L., Kaltoft K., Zeuthen J., Danø K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry. 1982 Dec 7;21(25):6410–6415. doi: 10.1021/bi00268a014. [DOI] [PubMed] [Google Scholar]
  40. Petersen H. H., Hansen M., Schousboe S. L., Andreasen P. A. Localization of epitopes for monoclonal antibodies to urokinase-type plasminogen activator: relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme. Eur J Biochem. 2001 Aug;268(16):4430–4439. doi: 10.1046/j.1432-1327.2001.02365.x. [DOI] [PubMed] [Google Scholar]
  41. Petersen L. C. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine). Eur J Biochem. 1997 Apr 15;245(2):316–323. doi: 10.1111/j.1432-1033.1997.00316.x. [DOI] [PubMed] [Google Scholar]
  42. Petersen L. C., Lund L. R., Nielsen L. S., Danø K., Skriver L. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem. 1988 Aug 15;263(23):11189–11195. [PubMed] [Google Scholar]
  43. Plotnick Michael I., Samakur Madhurika, Wang Zhi Mei, Liu Xhuzuo, Rubin Harvey, Schechter Norman M., Selwood Trevor. Heterogeneity in serpin-protease complexes as demonstrated by differences in the mechanism of complex breakdown. Biochemistry. 2002 Jan 8;41(1):334–342. doi: 10.1021/bi015650+. [DOI] [PubMed] [Google Scholar]
  44. Schnack Nielsen Boye, Rank Fritz, Engelholm Lars H., Holm Arne, Danø Keld, Behrendt Niels. Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells. Int J Cancer. 2002 Apr 10;98(5):656–664. doi: 10.1002/ijc.10227. [DOI] [PubMed] [Google Scholar]
  45. Skriver L., Nielsen L. S., Stephens R., Danø K. Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus. Eur J Biochem. 1982 May 17;124(2):409–414. doi: 10.1111/j.1432-1033.1982.tb06608.x. [DOI] [PubMed] [Google Scholar]
  46. Stack M. S., Johnson D. A. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J Biol Chem. 1994 Apr 1;269(13):9416–9419. [PubMed] [Google Scholar]
  47. Urano T., Sator de Serrano V., Chibber B. A., Castellino F. J. The control of the urokinase-catalyzed activation of human glutamic acid 1-plasminogen by positive and negative effectors. J Biol Chem. 1987 Nov 25;262(33):15959–15964. [PubMed] [Google Scholar]
  48. Wilczynska M., Fa M., Ohlsson P. I., Ny T. The inhibition mechanism of serpins. Evidence that the mobile reactive center loop is cleaved in the native protease-inhibitor complex. J Biol Chem. 1995 Dec 15;270(50):29652–29655. doi: 10.1074/jbc.270.50.29652. [DOI] [PubMed] [Google Scholar]
  49. Ye S., Goldsmith E. J. Serpins and other covalent protease inhibitors. Curr Opin Struct Biol. 2001 Dec;11(6):740–745. doi: 10.1016/s0959-440x(01)00275-5. [DOI] [PubMed] [Google Scholar]
  50. Zhou H. M., Nichols A., Meda P., Vassalli J. D. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J. 2000 Sep 1;19(17):4817–4826. doi: 10.1093/emboj/19.17.4817. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES